Beta-2 Microglobulin (β2M)
A dual marker — tubular kidney damage AND haematological malignancy staging
Beta-2 microglobulin is a small protein shed from every nucleated cell. When kidneys fail, it accumulates in blood — and when lymphocytes or myeloma cells proliferate rapidly, it surges. Its dual role makes it one of the few biomarkers used in both nephrology and haematology.
Beta-2 microglobulin is the light chain of MHC class I molecules expressed on all nucleated cells. It is freely filtered by the glomerulus (small size, no charge barrier) and almost completely reabsorbed (99.9%) and catabolised in the proximal tubule. Elevated serum β2M indicates either: (1) reduced tubular reabsorption due to CKD/tubular injury, or (2) increased production from rapidly proliferating lymphoid or myeloid cells. Urine β2M elevation specifically indicates proximal tubular damage (tubular, not glomerular, proteinuria).
Reference Ranges
How clinicians interpret Beta-2 Microglobulin (β2M) results — from optimal to concerning.
⚠ Reference ranges vary by laboratory and assay. Always interpret your result in context of your laboratory's own reference intervals and your clinical presentation.
What raises Beta-2 Microglobulin (β2M)
β2M is renally cleared — CKD reduces tubular catabolism, causing accumulation proportional to GFR loss.
Malignant plasma cells have high cell turnover — β2M release is massive. β2M is the single most important prognostic marker in myeloma (ISS staging).
Rapidly proliferating lymphoma cells shed β2M — useful for disease activity monitoring and prognosis.
Immune activation and CD4/CD8 T-cell turnover elevate β2M — one of the earliest HIV disease activity markers before CD4 count falls.
Long-term dialysis patients accumulate β2M which polymerises into amyloid fibrils depositing in joints and bone — dialysis-related amyloidosis.
Marked lymphocyte/macrophage activation (autoimmune disease, severe infection) transiently elevates β2M.
What lowers Beta-2 Microglobulin (β2M)
Proteasome inhibitors, IMiDs — β2M falls with treatment response. Persistent elevation or re-elevation = relapse.
Restored tubular catabolism normalises serum β2M — one measure of successful transplant function.
Haemodiafiltration (HDF) removes β2M more effectively than standard haemodialysis — used to prevent dialysis amyloidosis.
Conditions this biomarker signals
When Beta-2 Microglobulin (β2M) is outside normal range, these are the most clinically significant possibilities.
ISS stage I: β2M < 3.5 mg/L. Stage III: β2M ≥ 5.5 mg/L. Most important single prognostic factor in myeloma.
Urine β2M elevation specifically identifies tubular proteinuria (proximal tubular damage) vs glomerular proteinuria (albumin-dominant).
Long-term dialysis (> 10 years) with persistently very high serum β2M — β2M amyloid deposits in carpal tunnel, shoulder joints.
β2M > 3.5 mg/L in HIV correlates with rapid CD4 decline and disease progression — historical marker now supplemented by viral load.
Which tests measure this biomarker
Beta-2 Microglobulin (β2M) may be included in or ordered alongside these panels.
Myeloma staging, CKD monitoring, lymphoma activity. Renally cleared — always interpret alongside creatinine/eGFR.
Proximal tubular damage marker — distinguishes tubular from glomerular proteinuria. Rises in Fanconi syndrome, heavy metal nephropathy, cadmium exposure.
β2M as an MHC class I component — from immune function to clinical marker
Beta-2 microglobulin is the invariant light chain of MHC class I molecules, expressed on all nucleated cells. MHC class I presents intracellular peptides to CD8+ T cells — central to immune surveillance and viral clearance. β2M is non-covalently attached to the alpha chain of MHC class I; when MHC class I molecules are recycled from the cell surface, free β2M is released into plasma. In the kidney, the low molecular weight and lack of negative charge make it a freely filtered, non-secreted marker — ideal for assessing both GFR (serum accumulation) and proximal tubular integrity (urine appearance indicating failed reabsorption).
β2M is the primary myeloma prognostic factor
The International Staging System (ISS) for multiple myeloma uses serum β2M as its primary variable: Stage I (β2M < 3.5 + albumin ≥ 3.5 g/dL) has median survival of 62 months; Stage III (β2M ≥ 5.5 mg/L) has median survival of 29 months. No other single laboratory value predicts myeloma outcome as powerfully as β2M at diagnosis.
Urine β2M identifies tubular vs glomerular proteinuria
Glomerular proteinuria is dominated by albumin (large, negatively charged). Tubular proteinuria contains small proteins (β2M, α1-microglobulin, retinol-binding protein) that filtered normally but failed tubular reabsorption. Urine β2M elevation with minimal albuminuria = proximal tubular damage — seen in Fanconi syndrome, heavy metal toxicity (cadmium, lead), contrast nephropathy, and NRTI antiretroviral toxicity.
Dialysis-related amyloidosis: β2M as pathogenic agent
After > 10 years of dialysis, accumulated β2M (11.8 kDa — too large for standard dialysis membranes) polymerises into amyloid fibrils. These deposit in musculoskeletal tissue, causing carpal tunnel syndrome, arthropathy, and pathological fractures. High-flux haemodiafiltration (HDF) removes β2M more effectively than standard HD — the primary prevention for DRA in long-term dialysis patients.
Clinical use — when and why this is ordered
How clinicians use Beta-2 Microglobulin (β2M) in practice — the real-world scenarios where it changes decisions.
Myeloma staging at diagnosis
β2M is ordered alongside albumin, SPEP, immunofixation, and free light chains at myeloma diagnosis — determines ISS stage and initial treatment intensity.
Myeloma treatment response monitoring
β2M should fall with effective treatment. Failure to fall or re-elevation indicates suboptimal response, clonal evolution, or relapse.
Tubular nephrotoxicity assessment
Urine β2M monitors for proximal tubular toxicity from tenofovir (HIV), platinum chemotherapy, cisplatin, and contrast agents — before creatinine rises.
Lymphoma disease activity
Serial serum β2M tracks non-Hodgkin lymphoma burden — rising β2M during surveillance precedes radiological relapse detection.